Not everyone who enters the music industry is able to experience rapid sales and fan base growth. Often times, the band or artists are quick to gain attention with a downward decline over a period of time. Most fans will start to find other artists to follow as most artists stick to the same kind of style of music. For the Chainsmokers, this is not how they want to be remembered.
Alex Pall and Andrew Taggart became friends through the meeting of the duo after their manager currently set up a chance meeting. Andrew was living in Maine and had taken interest in the music industry portion of DJ-ing. Alex Pall had been living in NYC for quite sometime and was working as a DJ throughout the NYC area.
When the duo came to meet, no one knew for sure that they would hit it off so well however they did. Since they met, they have spent countless hours working on their music. For the group, the typical release time for a single was around a months time. In their current album release however, they have taken more time to figure out their music and where they would like to see the music go to.
Alex Pall and Andrew Taggart have become life long friends who continue to do what they love most. They have included new people to their tracks and have changed their overall performance to include vocals where as prior to this album, it did not. The new changes made to their music has helped to increase their fan base as more fans are being lured over by the vocals put out on the tracks rather than just the beats coming from them.
The pair have spent a lot of time thinking about where they would like the music to venture over to and since they are always looking for new and exciting ways to bring more happiness to their fans, there is no telling where the band might stop at. For now, the Chainsmokers have been lucky enough to reach the top of the charts and hang out there unlike many others who have climbed to the top and declined rather quickly.
Plastic and Aesthetic Surgeon Dr. Sameer Jejurikar practices at the Dallas Plastic Surgery Institute. Board Certified in Plastic Surgery Dr. Jejurikar is affiliated with three Dallas area hospitals Dallas Medical Center, Texas Health Presbyterian Hospital, and Pine Creek Medical Center.
Dr. Sam Jejurikar did his undergraduate work at the University of Michigan. He earned his medical degree at UM’s School of Medicine and later completed his residency in plastic surgery at that school’s medical center. Dr. Jejurikar studied aesthetic surgery at the Manhattan Eye, Ear and Throat Hospital.
In 2012 only 26,100 out of the 870,000 physicians practicing in the US were honored with Compassionate Doctor Certification from Patients’ Choice. Dr. Sam Jejurikar was among those honorees. Compassionate Doctor Certification could be thought of as the Peoples’ Choice Awards of medicine. Recipients are chosen based on how their patients rate them in online reviews. Only practitioners who receive a nearly perfect rating from their patients are given the Patients’ Choice designation.
Dr. Jejurikar’s patients are as impressed by his warm and caring bedside manner as they are by his skills as a plastic surgeon. These skills are evidenced by the fact that he is licensed to practice in three states as well as his American Board of Plastic Surgery certification. Detail and patient-oriented Dr. Jejurikar only employs the very latest methods in plastic and aesthetic surgery.
Dr. Sam Jejurikar’s compassion is too great to be contained within the borders of the US. Over a quarter-million children in Bangladesh have cleft lips or palates. Dr. Jejurikar has made multiple trips as part of the Smile Bangladesh team to perform free corrective surgery on children whose lips or palates are cleft. People here at home who need, but cannot afford aesthetic surgery have also benefitted from Dr. Sam Jejurikar’s compassion and generosity.
5AM Ventures, a firm led by Scott Rocklage, is one of several medical investment firms investing in helping Expansion Therapeutics find a cure for myotonic dystrophy type 1. DM 1, as the disorder is better known, is a genetic disorder caused by RNAs molecules accumulating to a toxic level within the body.
Expansion Therapeutics will use the money invested by Scott Rocklage’s firm to attempt to develop a treatment protocol or medications that might treat or prevent DM 1. Scott Rocklage has used his expertise to help Expansion Therapeutics bring together a top research team to find answers to the DM 1 disorder.
Matthew D. Disney will head up the research team. Scott Rocklage believes that Dr. Disney has the experience necessary to help find a cure for DM 1. Learn more: https://www.dialdish.com/scott-rocklage-seeks-to-conquer-cancer-by-targeting-mutant-rna-molecules/
Dr. Rocklage, and the team at Expansion Therapeutics, will also be working on small molecule medications that will be utilized to treat DM 1. With the combination of these two approaches, it is hoped that a cure for DM 1 will be forthcoming in the near future.
Scott Rocklage has spent over 30 years within the field of healthcare management. During his career, he has helped in the development of several drugs in the clinical trials phase. Three important drugs that Dr. Rocklage helped to developed are approved and on the market helping patients today.
Dr. Rocklage has served as the CEO of both Cubist Pharmaceuticals and NycomedSalutar. He is on the board of several pharmaceutical companies including Epirus and Pulmatrix. He is also managing partner of 5AM Ventures. This firm is helping companies achieve breakthroughs in the development of new drugs and new treatments for a variety of diseases and conditions.